Pharma Stocks: Macquarie sees margin pressure in Q2, upgrades Dr Reddy’s and Alkem - Published OnOct 16, 2026 | 15:36 IST - Last Updated OnOct 16, 2026 | 15:36 IST Macquarie warns that pharma firms will face Q2 margin pressure from rising raw material and freight costs despite strong domestic demand. However, the firm upgraded Dr Reddy’s and Alkem Laboratories, highlighting growth and recovery drivers.
No articles in the last 24 hours. Expand to 1 week
